Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy

Annals of Surgical Oncology

Volumn 22, Issue 2, 2015, Pages 392-400

  Lee, Hee Jin ^a   Song, In Hye ^a   Seo, An Na ^b   Lim, Bora ^c   Kim, Joo Young ^d   Lee, Jeong Ju ^e   Park, In Ah ^a   Shin, Jinho ^a   Yu, Jong Han ^a   Ahn, Jin Hee ^a   Gong, Gyungyub ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d Korea University College of Medicine   (South Korea)

^e Seonam University of Medicine Myongji Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST NECROSIS; CANCER ADJUVANT THERAPY; CANCER SIZE; CARCINOMA IN SITU; CORRELATIONAL STUDY; FEMALE; HISTIOCYTOSIS; HISTOPATHOLOGY; HORMONE RECEPTOR NEGATIVE BREAST CANCER; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR NECROSIS; ADJUVANT THERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84921029154     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4054-2     Document Type: Article

References (24)

1. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.
2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–93.
3. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.
4. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–7.
5. Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005;94:255–63.
6. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22.
7. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, et al. Prevalence, morphologic features, and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444–55.
8. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009;20:628–35.
9. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13.
10. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112:17–26.
11. Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29:660–6.
12. McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011;18:3149–54.
13. Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol. 2009;20:636–41.
14. Moon HG, Han W, Ahn SK, Cho N, Moon WK, Im SA, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg. 2013;257:133–7.
15. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.
16. Bhargava R, Beriwal S, Striebel JM, Dabbs DJ. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol. 2010;18:113–8.
17. Dite GS, Makalic E, Schmidt DF, Giles GG, Hopper JL, Southey MC. Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry. Breast Cancer Res. 2012;14:R122.
18. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med. 2013. doi:10.1200/JCO.2013.50.9984.
19. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–7.
20. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother 2005;59(Suppl 2):S387–92.
21. Li SP, Padhani AR, Taylor NJ, Beresford MJ, Ah-See ML, Stirling JJ, et al. Vascular characterisation of triple-negative breast carcinomas using dynamic MRI. Eur Radiol. 2011;21:1364–73.
22. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13.
23. Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14:R129.
24. Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, et al. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 2014;145:615–23.